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Objectives: The purpose of this study was to profile altered patterns of
gene expression that characterize degenerative ascending thoracic aortic
aneurysms and to compare these patterns with those observed for infra-
renal abdominal aortic aneurysms.
Methods: Full-thickness aortic wall tissues were obtained during surgical
repair of degenerative thoracic aortic aneurysms and infrarenal abdominal
aortic aneurysms (n  4 each), with normal thoracic and abdominal
aortas from organ transplant donors used as control preparations. Radio-
labeled complementary DNA was prepared for each specimen and hy-
bridized to complementary DNA microarrays, and differential levels of
gene expression between aneurysmal and normal aortic tissues at each site were
assessed by parametric statistics.
Results: Of 1185 genes examined, 112 (9.5%) were differentially expressed (P 
.05) between thoracic aortic aneurysms and normal thoracic aorta, with 105 in-
creased and 7 decreased. There were 104 genes (8.8%) differentially expressed
between infrarenal abdominal aortic aneurysms and normal abdominal aorta (65
increased and 39 decreased). Quantitative increases in expression for 97 genes were
unique to thoracic aortic aneurysms, whereas increases for 61 genes were unique to
infrarenal abdominal aortic aneurysms. Although 8 gene products were significantly
altered in both thoracic and infrarenal abdominal aortic aneurysms, these changes
were directionally concordant for only 4 (matrix metalloproteinase 9/gelatinase B,
v-yes-1 oncogene, mitogen-activated protein kinase 9, and intercellular adhesion
molecule 1/CD54). Results for 9 genes were independently confirmed by quantita-
tive reverse transcriptase–polymerase chain reaction.
Conclusions: Thoracic aortic aneurysms and infrarenal abdominal aortic aneurysms
exhibit distinct patterns of gene expression relative to normal aorta from the same
sites, with most alterations being unique to each disease. Degenerative aneurysms
arising in different locations are thus characterized by a high degree of molecular
heterogeneity, reflecting different pathophysiologic mechanisms.
Degenerative aortic aneurysms represent a relatively common con-dition responsible for considerable cardiovascular morbidity andmortality. Although aneurysms may arise at any site along thecourse of the aorta, they most frequently occur in the infrarenalabdominal aorta or the descending portion of the thoracic aorta.The ascending thoracic aorta is another common location for
aortic aneurysms, which may develop in association with hypertension and spon-
taneous (type A) aortic dissection, congenital valvular abnormalities (eg, bicuspid
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aortic valves1-3), and inherited connective tissue disorders
(eg, Ehlers-Danlos syndrome type IV,4 Marfan syndrome,5
and other fibrillinopathies6,7). Genetic linkage studies have
also revealed several new chromosomal loci associated with
familial forms of thoracic aortic aneurysm and dissection,
including a locus at 11q23.2-q24 and another at 5q13-14.8,9
Although candidate genes at each of these loci have been
identified and examined, the genes responsible for aortic
disease in these families have not yet been identified. Thus,
despite significant progress during the past decade toward
understanding the pathogenesis of aneurysmal disease, the
specific factors causing aneurysmal degeneration in various
locations remain unresolved.
Although it might be assumed that the pathophysiology
of aortic aneurysms is homogeneous regardless of location,
the histopathologic features of thoracic aortic aneurysms
(TAAs) are quite different from those that characterize
abdominal aortic aneurysms (AAAs). The microscopic find-
ings in TAAs are most frequently described by the term
“cystic medial necrosis,” reflecting a noninflammatory loss
of medial smooth muscle cells (SMCs), fragmentation of
elastic fibers, and mucoid degeneration.10,11 In contrast, the
histopathologic features of AAAs are dominated by severe
intimal atherosclerosis, chronic transmural inflammation,
and destructive remodeling of the elastic media.12,13 Al-
though it is clear that each of these pathologic patterns can
be associated with aneurysm formation, it is uncertain how
they are related to the underlying etiology and pathophysi-
ology of aortic disease arising in these two different loca-
tions.14
Further evidence suggests that the cellular and molecular
mechanisms underlying various forms of aneurysmal dis-
ease may also be different. Studies on human and experi-
mental AAAs have focused on increased expression and
tissue localization of elastin- and collagen-degrading en-
zymes, particularly matrix metalloproteinases (MMPs), cys-
teine proteases, and their respective inhibitors.15-18 Genes
encoding a number of proinflammatory cytokines, chemo-
tactic factors, and cell adhesion molecules have also been
implicated in AAAs,19 and depletion of vascular SMCs may
have an important influence the process of vascular remod-
eling that occurs during aneurysmal degeneration.20,21 Stud-
ies focusing on TAAs have indicated that cystic medial
necrosis is also associated with elastin degradation and
fragmentation,22,23 SMC depletion and apoptosis,24 and in-
creased expression of at least some MMPs.25,26. However,
the absence of a significant inflammatory response implies
alternative mechanisms of aneurysm formation in TAAs
versus AAAs, perhaps related to the different embryologic
origin of cells populating the ascending and infrarenal aorta,
differing structural properties and propensities toward ath-
erosclerotic degeneration, or the distinct hemodynamic con-
ditions that distinguish these two areas. Despite ongoing
investigations regarding the fundamental mechanisms re-
sponsible for aneurysmal degeneration, the spectrum of
molecular alterations that may occur in aneurysms at dif-
ferent sites remains unknown.
The development of microchip- and membrane-based
complementary DNA (cDNA) arrays has recently made it
possible to examine simultaneous expression of thousands
of gene products in the same experiment.27-31 Microarray
techniques have been applied to diverse disease processes,
including human atherosclerosis and AAAs, yielding valu-
able insights into the pathologic profiles of altered gene
expression in these conditions.32-34 Given the potential dis-
coveries that might arise from more comprehensive under-
standing of altered gene expression in different forms of
aneurysmal disease, the purpose of this study was to estab-
lish a transcriptional profile of aortic wall gene expression
that occurs in TAAs relative to normal ascending aorta
(NTA). A second goal of this study was to compare altered
patterns of gene expression between TAAs and AAAs to
determine the similarities and differences that may exist
between these two conditions.
Methods
Aortic Tissues
Full-thickness aortic wall specimens were obtained from 4 patients
undergoing elective surgical repair of asymptomatic TAAs (2 men
and 2 women, ages 49, 78, 82, and 52 years, mean age 65.3  4.3
years). The mean aneurysm size was 6.0  0.4 cm by computed
tomography (5.0, 5.0, 8.0, and 6.0 cm). None of these lesions were
associated with aortic dissection, congenital aortic valve abnor-
malities, inherited connective tissue disorders, or familial forms of
aneurysmal disease, and no patients had AAAs. For comparison, 4
full-thickness specimens of NTA were obtained from cadaveric
organ transplant donors without visible evidence of atherosclerosis
(2 men and 2 women, ages 25, 40, 59, and 38 years, mean age 40.5
 3.5 years).
A second series of full-thickness aortic wall specimens was
obtained from 4 patients undergoing elective repair of asymptom-
atic AAAs, including 2 men and 2 women (ages 84, 80, 76, and 57
years, mean age 74.3  6.0 years). The mean aneurysm size was
5.7  0.3 cm by computed tomography (5.5, 5.1, 6.3, and 6.0 cm).
None of the patients had “inflammatory” AAAs or aneurysms
elsewhere. For comparison, specimens of normal infrarenal ab-
dominal aorta (NAA) without visible evidence of atherosclerosis
were obtained from 4 cadaveric organ transplant donors (3 men
and 1 woman, ages 43, 18, 14, and 36 years, mean age 27.8  7.0
years).
All tissue specimens were snap-frozen in liquid nitrogen im-
mediately on procurement and stored at70°C before nucleic acid
extraction. All tissues were obtained with approval by the Wash-
ington University School of Medicine human research subjects
committee.
Light Microscopy
Representative aortic tissue samples corresponding to each of the
four groups were fixed in 10% neutral buffered formalin and
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processed for routine embedding in paraffin. Sections (5 m) were
stained with Verhoeff–van Geisen stain for elastin and viewed by
light microscopy.
RNA Samples
Each aortic tissue sample (n  16) was pulverized under liquid
nitrogen, and total RNA was isolated with Trizol reagent (Gibco
BRL, Grand Island, NY).35,36 RNA samples were further extracted
with phenol and chloroform to eliminate excess protein, and re-
sidual DNA contamination was eliminated with RQ1 ribonuclease-
free deoxyribonuclease (Promega Corporation, Madison, Wis). In
some cases the samples were enriched for messenger RNA by
incubation with streptavidin-coated magnetic beads and biotinyl-
ated oligodeoxythymidine (Atlas Pure Total RNA Labeling Sys-
tem; Clontech, Palo Alto, Calif).
Preparation of Radiolabeled cDNA and Membrane
Hybridization
Radiolabeled cDNA was prepared with reagents and protocols
provided with the AtlasArray Human 1.2 I cDNA Expression
Array kit from CLONTECH (CLONTECH Laboratories, Inc, Palo
Alto, Calif), as previously described elsewhere.33 For each of the
16 samples, 5 g total RNA was incubated with a mixture of
array-specific oligonucleotide primers and 400 units of Superscript
II reverse transcriptase (Gibco) in the presence of deoxyadenosine
triphosphate labeled with phosphorus 32 (Amersham Pharmacia
Biotech, Piscataway, NJ). Labeled cDNA samples were purified by
column chromatography to remove unincorporated isotope before
use. Each cDNA sample was mixed into hybridization buffer
(ExpressHyb; CLONTECH) and then incubated overnight at 68°C
with a nylon membrane containing bound cDNA clones corre-
sponding to 1185 known genes (AtlasArray Human 1.2 I; CLON-
TECH). Membranes were washed according to the manufacturer’s
protocol, exposed to a phosphor screen (Eastman Kodak Com-
pany, Rochester, NY), and subsequently scanned (Molecular Dy-
namics, Inc, Sunnyvale, Calif). Densitometry readings for each
gene were obtained with AtlasImage 1.01a (CLONTECH) and
adjusted for the background density adjacent to each immobilized
target cDNA on the same membrane.33
Data Analysis
The relative signal intensity for each gene on a given membrane
was calculated as a fraction of the total signal intensity for all
genes on the same membrane. The entire data set of adjusted
intensity levels was entered into a commercially available data
analysis and display platform specifically designed for high-den-
sity genomic expression studies (GeneSpring 4.0.4; Silicon Genet-
ics, Redwood, Calif). Data were thereafter accessible for both
mathematic computations and a number of different color graphic
analytic display options, including the construction of experimen-
tal gene trees (dendrograms), self-organizing maps, statistical
comparisons, and hierarchic cluster analysis (for reviews of these
techniques, see Eisen and colleagues29 and Lockhart and cowork-
ers31 and references contained therein).
For each gene represented on the microarray, the mean ratio of
expression (or fold change) in aneurysmal tissue was calculated by
comparison with the mean values obtained for normal aorta from
the same location (TAAs vs NTA and AAAs vs NAA). The data
set was then examined with a parametric comparisons test to
identify genes exhibiting different levels of expression between
aneurysms and normal aorta.29,31 The two lists of differentially
expressed genes were then compared to identify similarities and
differences in the patterns of altered gene expression between
TAAs and AAAs. To examine the consistency of changes in gene
expression within the specimens from each group, the upper limit
of normal expression was determined as the mean plus 2 SD of
values obtained for the 4 normal aorta specimens. For genes
reported to be expressed at increased levels, the number of indi-
vidual aneurysm specimens exhibiting expression above the upper
limit of normal was determined and recorded as a percentage of the
total (n  4) for each group. A similar analysis was performed for
genes reported to be expressed at decreased levels, by determining
the percentage of aneurysm specimens in which expression was
below the lower limit of normal (mean minus 2 SD).
Reverse Transcription–Quantitative Polymerase Chain
Reaction
To independently confirm results obtained by cDNA microarray
analysis, the relative expression patterns of 9 selected genes were
also measured by reverse transcription–quantitative polymerase
chain reaction (RT-qPCR) assays. Reverse transcription was per-
formed with 1 g total RNA isolated from each aortic tissue
sample (n  16) along with a GeneAmp 2400 thermal cycler and
reagents from PE Biosystems (5.5-mmol/L magnesium chloride,
0.5-mol/L deoxyribonucleoside triphosphates, 1.25-U/L Multi-
Scribe Reverse Transcriptase, and 2.5-mol/L random hexamers;
PE Biosystems, Foster City, Calif). The cDNA samples were used
for real-time detection of PCR amplification with SYBR Green, a
fluorescent DNA binding dye (GeneAmp 5700 Sequence Detec-
tion System; PE Biosystems), as previously described elsewhere.36
Primer pairs were selected with PrimerExpress version 1.6 soft-
ware (PE Biosystems) to amplify the following gene products:
MMP-9/gelatinase-B (GenBank J05070), interleukin (IL) 6 signal
transducer gp130 (GenBank M57230), v-yes-1 Yamaguchi sar-
coma virus–related oncogene (GenBank M16038), apolipoprotein
E (GenBank M12529), IL-8 (GenBank Y00787), IL-1 (GenBank
K02770), tumor necrosis factor (TNF)  (GenBank X01394),
vascular cell adhesion molecule 1 (GenBank M30257), cathepsin
D (GenBank M11233), and -actin (GenBank X00351).
All real-time polymerase chain reactions (50 L) were per-
formed in duplicate with 10 ng cDNA and kit reagents, with initial
incubations at 50°C (2 minutes) and 95°C (10 minutes) for Am-
pErase and AmpliTaq Gold activation, respectively, followed by
40 cycles of polymerase chain reaction (95°C for 15 seconds
alternating with 60°C for 1 minute). Direct detection of reaction
products was monitored by measuring the increase in fluorescence
caused by the binding of SYBR Green I to double-stranded DNA
products, along with an internal reference standard (ROX). Fluo-
rescence signals were analyzed with the GeneAmp 5700 Sequence
Detection System software (SDS version 1.3; PE Biosystems)
according to the manufacturer’s recommendations. All quantitative
results were normalized to the mean concentration of -actin
messenger RNA to account for variability in the quality of total
RNA and the efficiency of reverse transcription between samples.
For each gene, statistical differences in expression between TAAs
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and NTA and between AAAs and NAA were analyzed by the
paired Student t test.
Results
Morphologic Appearance of Aneurysmal Tissues
Light microscopy of TAA tissues revealed disruption and
disorganization of medial elastic fibers in the absence of
significant inflammatory changes, along with areas of
ground substance accumulation considered characteristic of
cystic medial necrosis (Figure 1). In contrast, AAAs were
characterized by more extreme destruction of medial elastic
fibers with replacement by a fibrocollagenous extracellular
matrix and depletion of medial SMCs. AAAs also exhibited
infiltration of the media and adventitia by mononuclear
inflammatory cells, often in direct association with degen-
erating elastic fibers (Figure 1).
Microarray Data
Representative hybridization blots for microarrays prepared
from specimens of aneurysmal and normal thoracic aorta
are shown in Figure 2. After phosphoimaging to quantify
the relative expression level of each gene, data were cor-
rected for the adjacent background intensity and normalized
as a fraction of the total intensity observed on the entire blot.
The complete data sets (adjusted intensities for each gene on
each of 16 different arrays) were then entered into the
GeneSpring program for further analysis. Figure 2, B, illus-
trates a color display map depicting the relative levels of
expression for all 1185 genes on the array in each sample of
TAAs and NTA.
Gene Expression Profiles of Aneurysmal Tissues
One hundred twelve of 1185 genes represented on the
microarray (9.5%) were differentially expressed between
TAAs and NTA (P  .05), with 105 exhibiting a significant
increase in expression and 7 exhibiting a significant de-
crease (Table 1). The magnitude of increased expression
was at least 10-fold greater in TAAs than NTA for 17 of
these transcripts, with the greatest increases observed for
protein kinase C (PKC)  (100-fold), uracil-DNA glyco-
sidase (44-fold), lymphotoxin  (41-fold), TNF- (27-fold),
and the TNF receptor superfamily member CD27 (18-fold).
With regard to the consistency of these results, the alter-
ations described were observed in at least 3 of the 4 indi-
vidual TAA specimens for 95 of the 112 genes (85%),
including 92 of the 105 genes (88%) exhibiting increased
expression and 3 of the 7 genes (43%) exhibiting decreased
expression (Table 1).
One hundred four of 1185 genes (8.8%) were differen-
tially expressed between AAAs and NAA (P  .05), with
65 exhibiting a significant increase in expression and 39
exhibiting a significant decrease (Table 2). Only 6 of these
transcripts were increased greater than 10-fold between
Figure 1. Histopathology of aortic aneurysms. Representative sections of aortic wall tissue stained with Verhoeff–
van Geisen for elastin (dark purple fibers). Compared with NTA, TAAs exhibited disruption, fragmentation and
disorganization of medial elastic fibers in absence of significant inflammatory changes, along with other
characteristic features of cystic medial necrosis (upper panels). AAAs exhibited more extreme destruction of
medial elastin and replacement by fibrocollagenous extracellular matrix (pink), along with depletion of medial
SMCs and mononuclear inflammatory cell infiltration in direct association with areas of elastic fiber degeneration
(lower panels).
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Figure 2. Microarray analysis of gene expression during aneurysm development. A, Representative autoradio-
graphs for AtlasArray Human 1.2 I membranes (CLONTECH) blotted with phosphorus 32–labeled cDNA derived from
NTA and TAA. Each blot contains bound cDNA clones from 1185 distinct gene products that can be identified by
superimposing orientation grid provided by manufacturer, with each gene located by sectors A through F, columns
01 through 14, and rows a through n (sector G denotes panel of 9 housekeeping genes; see manufacturer website
for further details at http://atlasinfo.clontech.com). Differences in gene expression between blots can be visualized
in higher resolution panels from the areas highlighted in yellow, as shown on far right (blue asterisks denote 3
genes exhibiting decreased expression in TAAs vs NTA and red asterisks denote 2 genes exhibiting increased
expression). B, Color display illustrating relative levels of expression for all 1185 genes represented on AtlasArray
Human 1.2 I microarray as generated by GeneSpring version 4.0.4 software (Silicon Genetics). Data shown reflect
levels of relative gene expression (normalized relative intensities) for each individual gene in 4 specimens of NTA
and 4 TAAs, where each gene is represented by single vertical band oriented according to array code shown
above. Color bar (below) indicates spectrum of normalized relative intensities shown on color display, ranging
from blue (low-level expression) to purple (mean expression) to red (high-level expression).
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TABLE 1. One hundred twelve genes exhibiting altered expression in TAAs
Array code
GenBank
reference Gene or protein name NTA TAA A/N ratio P value
Conservation
(%)
B09i Z15108 PKC- 0 0 163 66 100 .048 100
C14n X15653 Uracil-DNA glycosylase 3 3 131 41 43.59 .020 100
C10f L11015 Lymphotoxin  10 10 396 129 41.05 .024 100
C08f X01394 TNF- 23 9 619 240 26.63 .047 100
C03g M63928 CD27 (TNF receptor superfamily) 106 38 1927 638 18.13 .029 100
B10i L07032 PKC- 6 6 81 3 14.05 .001 100
D13b U31215 Glutamate receptor metabotropic 1 5 5 63 22 13.72 .039 75
B13c M12154 Antigen p97 (melanotransferrin) 9 9 112 34 12.43 .026 75
B08j M61906 PI-3-kinase, regulatory subunit (p85 ) 9 9 101 31 11.64 .029 75
B13k M31158 Cyclic adenosine monophospate–dependent
protein kinase, type II
11 8 130 45 11.54 .041 75
B11c M12530 Transferrin 10 6 117 39 11.26 .035 100
A14e M21574 Platelet-derived growth factor receptor  113 77 1246 419 11.04 .038 75
C14c M97934 STAT2 30 9 333 47 10.95 .001 100
B03n M28213 RAB2 (ras oncogene family) 261 98 2813 822 10.80 .022 100
B14l X14034 Phospholipase C2 24 16 258 75 10.60 .023 100
D09i Y00264 Amyloid  (A4) precursor protein 976 110 10,047 3463 10.30 .040 100
E10a M62829 Early growth response 1 3330 1222 33,837 8606 10.16 .013 100
A03h X59798 Cyclin D1 62 26 611 191 9.89 .029 75
D06j X79067 EGF-response factor 1 1422 255 13,772 4690 9.68 .039 100
D13a M55983 Deoxyribonuclease I 6 6 52 18 9.05 .048 50
A09g M35410 Insulinlike growth factor binding protein 2 627 156 5626 1679 8.97 .025 75
F07m J05070 MMP-9/gelatinase B 151 26 1306 367 8.64 .020 75
E07a M36542 POU domain class 2 transcription factor 2 12 7 98 18 8.33 .004 100
B09g U12535 EGF receptor pathway substrate 8 44 27 361 115 8.10 .037 75
C09f D12614 Lymphotoxin  15 9 120 23 8.03 .006 100
C01f L34075 FK506 binding protein 12 (FRAP) 32 8 252 60 7.99 .011 100
E03h M30257 Vascular cell adhesion molecule 1 70 13 545 81 7.81 .001 100
B03m X80907 PI-3-kinase, regulatory subunit (p85 ) 32 16 240 44 7.45 .004 100
C02e J03075 PKC substrate 80K-H 588 175 4118 789 7.00 .005 100
E09l D11086 IL-2 receptor  262 75 1787 535 6.81 .030 75
B02n X08004 RAP1B (ras oncogene family) 274 140 1850 470 6.75 .018 75
C13a L11329 Dual-specificity phosphatase 2 (PAC-1) 21 9 140 32 6.74 .011 100
A04d X56681 jun D proto-oncogene 228 43 1502 503 6.59 .045 75
B14m X16316 vav-1 oncogene 54 34 352 114 6.53 .046 75
C12b U14188 Ephrin A4 51 5 316 53 6.20 .003 100
C02f U61166 SH3 p17 protein 63 9 387 77 6.19 .006 100
C03a M31724 Protein tyrosine phosphatase type 1 52 26 324 92 6.18 .030 75
F13a X14672 N-acetyltransferase 2 51 19 314 49 6.17 .003 100
C09e AF076974 Transform/transcript domain-associated protein 175 37 1079 114 6.15 .001 100
A02f D17517 TYR03 protein tyrosine kinase 75 29 459 152 6.15 .047 75
B12d M57230 IL-6 signal transducer gp130 43 9 261 86 6.14 .045 75
C13c M97935 STAT-1 60 31 358 21 5.94 .001 100
C08h U39613 ICE-LAP3 22 13 131 22 5.81 .006 75
C10d M23379 RAS p21 protein activator 92 30 521 112 5.67 .010 100
B10g M15800 mal, T-cell differentiation protein 55 14 302 64 5.49 .009 100
C10c X14454 Interferon regulatory factor 1 119 24 651 78 5.49 .001 100
F10i K02770 IL-1 642 119 3472 1080 5.41 .040 100
C14e M23410 Junction plakoglobin 104 22 563 40 5.39 .001 100
E11c M97190 Sp2 transcription factor 146 7 771 243 5.28 .042 100
A04h D13639 Cyclin D2 67 22 336 16 5.00 .001 100
F13m M11233 Cathepsin D 3975 2371 19,697 1763 4.96 .002 100
C13d S76965 Cyclic adenosine monophosphate–dependent
protein kinase inhibitor 
58 21 284 64 4.88 .015 100
C09d X69550 Rho GDP dissociation inhibitor  2949 938 14,297 1549 4.85 .001 100
G31 M11886 MHC class I C 3264 1153 15,513 3565 4.75 .017 75
B02g M16038 v-yes-1 oncogene 127 69 602 162 4.75 .035 75
E03e M64673 Heat shock transcription factor 1 746 107 3507 733 4.70 .010 100
E01e L12579 Cut-like 1 (Drosophila) 293 55 1352 306 4.61 .014 100
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E09a M62810 Mitochondrial transcription factor 1 115 39 524 145 4.58 .034 75
E12e M96824 Nucleobindin 1 2430 732 10,831 2299 4.46 .013 100
E01f U04847 SWI/SNF-related member 1 615 114 2605 347 4.23 .002 100
B05j L31951 Mitogen-activated protein kinase 9 70 23 292 53 4.18 .008 75
D09e M65212 Catechol-O-methyltransferase 1376 458 5711 1545 4.15 .036 75
D12d AF016709 Purinergic receptor P2X 18 11 69 18 3.93 .048 75
F14m U41766 ADAM-9 230 48 895 134 3.88 .003 100
E14g J03132 Intercellular adhesion molecule 1/CD54 1281 809 4960 699 3.87 .014 50
A05h M92287 Cyclin D3 153 63 588 39 3.84 .001 100
B04g U07707 Epidermal growth factor receptor pathway
substrate 15
162 46 601 142 3.71 .025 100
F14l U78095 Serine protease inhibitor 2 454 164 1681 406 3.70 .031 75
C13e X61615 Leukemia inhibitory factor receptor 65 32 230 41 3.56 .019 50
C11b U56976 Phosphodiesterase IB, calmodulin dependent 61 35 213 18 3.51 .008 50
B14h U25265 Mitogen-activated protein kinase 5 116 26 393 108 3.40 .047 100
A09h M77234 Ribosomal protein S3A 6819 3384 22,853 4397 3.35 .028 75
A02h M25753 Cyclin B1 136 29 453 107 3.32 .029 75
C11g X76981 Adenosine A3 receptor 118 38 386 92 3.28 .035 75
C12a M63960 Protein phosphatase-1, catalytic subunit  665 196 2125 363 3.20 .012 100
C08e X75621 Tuberous sclerosis 2 250 51 793 89 3.17 .002 100
C02i X04106 Calpain 4, small subunit (30 kd) 6392 1247 20,202 3665 3.16 .012 100
B05e U12140 Neurotrophic tyrosine kinase receptor type 2 61 23 191 28 3.14 .011 75
C12c L19067 v-rel (nuclear factor B related) p65 196 34 613 131 3.13 .022 75
E13e U02326 Neuregulin 1 90 15 280 75 3.11 .048 100
C03h X96586 Sphingomyelinase activation-associated factor 171 50 532 125 3.11 .037 75
B06h U09578 Mitogen-activated protein kinase-activated
protein kinase 3
53 26 158 21 2.98 .020 50
A05c M80359 Mitogen-activated protein/microtubule affinity-
regulating kinase 3
213 59 632 157 2.97 .047 75
C02g Y09392 TNF receptor superfamily member 12 139 34 402 73 2.88 .017 75
C07h U20537 Caspase 6 78 20 219 30 2.81 .008 75
A04i M14505 Cyclin-dependent kinase 4 275 78 751 156 2.73 .034 75
B07n M28212 RAB6 243 49 641 145 2.64 .040 75
C07e U17032 Rho guanosine triphosphatase activating
protein 5
86 15 225 49 2.62 .035 75
C07j X86779 Fas-activated serine/threonine kinase 344 72 884 125 2.57 .010 100
D10l U58198 IL enhancer binding factor 1 126 25 320 70 2.53 .041 50
E14e U03494 Transcription factor CP2 122 29 304 68 2.48 .049 50
E06i M59911 Integrin 3 163 32 397 84 2.44 .040 75
E05j M23197 CD33 antigen (gp67) 109 10 264 46 2.42 .016 100
C04h U13021 Caspase 2 88 21 209 21 2.38 .006 75
A04f X16416 v-abl 116 27 274 25 2.36 .006 100
C10b U40370 Phosphodiesterase 1A, calmodulin dependent 185 50 436 89 2.36 .049 75
F07k X87212 Cathepsin C 916 281 2138 355 2.33 .036 50
E06k U11814 Keratinocyte growth factor receptor 66 12 151 14 2.28 .003 100
D10k AF069733 Transcriptional adaptor 3 185 20 400 85 2.16 .048 50
F13c M22489 Bone morphogenetic protein 2 198 67 405 47 2.05 .044 50
C02l X98093 Polymerase (DNA directed)  183 28 366 53 2.00 .022 75
F12j M24398 Parathymosin 6374 1193 12,240 1778 1.92 .034 75
E04j M21097 CD19 antigen 91 17 172 10 1.89 .007 75
E01j X87838 Catenin 1 (88 kd) 353 59 567 54 1.61 .036 50
F06b M11717 Heat shock 70 kd protein 1A 5558 990 8556 678 1.54 .047 50
E11m U77604 Microsomal glutathione S-transferase 2 1448 44 1040 141 0.72 .032 0
C06n U07418 mutL homolog 1 (Escherichia coli) 36,628 4866 21,048 2038 0.57 .026 25
E12l U00672 IL-10 receptor  180 15 69 24 0.38 .008 100
C05k U32944 Dynein cytoplasmic light polypeptide 13,323 983 4965 1028 0.37 .001 100
A08l M63618 Bullous pemphigoid antigen 1 (230/240 kd) 731 158 227 18 0.31 .019 0
F01g M96956 Teratocarcinoma-derived growth factor 3 1296 439 151 59 0.12 .041 25
D11h U32376 Discs, large (Drosophila) homolog 2 70 23 6 6 0.09 .034 75
A/N, Abnormal/normal ratio.
Surgery for Acquired Cardiovascular Disease Absi et al
350 The Journal of Thoracic and Cardiovascular Surgery ● August 2003
A
CD




reference Gene or protein name NAA AAA A/N ratio P value
Conservation
(%)
F07m J05070 MMP-9/gelatinase B 96 81 8317 2590 86.52 .019 100
B04d L25259 CD86 antigen (B7-2 antigen) 34 34 1463 237 43.42 .001 100
E10f L36720 Bystin-like 31 31 1277 484 40.77 .042 75
B04c M12529 Apolipoprotein E 993 570 14,459 4144 14.56 .018 100
E03i M15395 Integrin 2 256 191 3278 707 12.79 .006 100
B05k U43408 Nonreceptor tyrosine kinase 1 65 65 767 235 11.87 .028 100
B03j U09607 Janus kinase 3 359 157 2999 968 8.35 .036 100
E09g M73780 Integrin 8 430 329 3443 749 8.00 .010 100
F14g Y00787 IL-8 2150 950 15,494 5313 7.21 .048 75
B05i D10495 PKC- 458 282 3226 994 7.04 .037 75
E08c X55122 GATA-3 553 292 3774 736 6.83 .007 100
E04h M30640 Selectin E 392 164 2566 615 6.54 .014 75
C04j M63167 v-akt (rac protein kinase ) 260 187 1698 328 6.53 .009 100
B02j M35203 Janus kinase 1 263 100 1650 546 6.27 .046 75
E10b M97676 msh homolog 1 (Drosophila) 1249 335 7725 2032 6.19 .020 100
B02k AJ000512 Serum glucocorticoid-regulated kinase 590 194 3478 907 5.89 .021 75
E02i L12002 Integrin 4 256 256 1462 349 5.72 .032 50
E01c U08015 Nuclear factor of activated T cells 295 91 1659 521 5.63 .042 75
E01d U43188 E74-like factor 2 345 164 1892 521 5.48 .030 100
C04k U45880 Baculoviral IAP repeat-containing 4 278 98 1512 435 5.44 .032 75
A11l M81750 Myeloid cell nuclear differentiation antigen 2331 911 12,077 708 5.18 .001 100
E06e D28468 Albumin D box-binding protein 1429 661 7399 722 5.18 .001 100
E04a M16937 Homeo box B7 1121 604 5650 1728 5.04 .048 75
B13d D10924 CXC chemokine receptor-4 (fusin) 2254 588 11,172 1767 4.96 .003 100
E05g D83542 Cadherin 15 (M-cadherin) 571 465 2704 722 4.73 .048 50
E06h M34064 Cadherin 2 (N-cadherin) 435 264 2018 456 4.64 .024 75
F08k X07549 Cathepsin H 2914 1216 13,310 3460 4.57 .030 75
C10a L14778 Calcineurin A  1411 717 6394 1268 4.53 .014 75
F12f M74178 Macrophage stimulating 1 2307 906 10297 1592 4.46 .005 100
B07g AF055581 Lymphocyte adaptor protein 647 267 2865 634 4.42 .018 75
E05c U10324 IL enhancer binding factor 3 (90 kd) 844 440 3712 705 4.40 .014 75
E09b M97287 Special AT-rich sequence binding protein 1 1226 262 5290 1192 4.31 .016 100
B01e U08839 Urinary-type plasminogen activator receptor 500 418 2155 305 4.31 .019 50
E11g M14219 Decorin 3497 1447 14,855 4031 4.25 .038 75
E08d M58603 Nuclear factor B enhancer p105 805 330 3234 534 4.02 .008 75
E14i Y00796 Integrin L (CD11a antigen) 3269 898 12,634 1824 3.86 .004 100
E06d AF072825 raf-responsive zincfinger protein 491 293 1893 321 3.86 .018 75
E07b M93255 Friend leukemia virus integration 1 3564 958 13,673 2286 3.84 .007 100
B06d M62424 Coagulation factor II (thrombin) receptor 2657 929 10,182 593 3.83 .001 100
A09c K00650 v-fos 2290 819 8080 1584 3.53 .018 75
B05j L31951 Mitogen-activated protein kinase 9 479 195 1629 427 3.40 .050 50
A12l D38305 Transducer of ERBB2-1 935 512 3170 679 3.39 .039 50
B02m U86453 PI-3-kinase  polypeptide 626 246 2103 494 3.36 .037 75
B05l U08316 Ribosomal S6 kinase 3 1095 440 3671 595 3.35 .013 75
E09d D45132 Zinc-finger DNA-binding protein 519 156 1735 164 3.34 .002 100
B05d D10925 Chemokine (C-C motif) receptor 1 419 194 1343 273 3.21 .033 75
C02k L09210 Inducible nitric oxide synthase (nitric oxide
synthase 2)
381 196 1168 242 3.07 .045 50
B03l L07597 Ribosomal S6 kinase 1 963 413 2914 420 3.03 .016 75
E08b M96944 Paired box gene 5 1491 566 4393 600 2.95 .013 50
B04k L32976 Mitogen-activated protein kinase 11 1474 878 4337 198 2.94 .020 0
B04m U78576 PI-4-phosphate 5-kinase type 1  684 367 2010 324 2.94 .035 50
E14g J03132 Intercellular adhesion molecule 1/CD54 6563 2678 18,441 2215 2.81 .014 50
F14j Z71621 Wingless-type MMTV integration site 2B 3676 1447 10,078 1651 2.74 .027 75
F13k D45248 Proteasome activator subunit 2 4268 1256 11,121 2172 2.61 .034 75
E07e L11672 Zinc finger protein 91 (HPF7, HTF10) 3639 1152 9444 683 2.60 .005 75
B07m X15014 v-ral 1573 296 3966 708 2.52 .021 75
B05n M28211 RAB4 (ras oncogene family) 335 107 823 150 2.46 .038 50
F06d M29645 Insulinlike growth factor 2 (somatomedin A) 1221 433 2954 358 2.42 .022 25
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AAAs and NAA, including MMP-9/gelatinase B (86-fold),
CD86/B7-2 antigen (43-fold), bystin-like (41-fold), apoli-
poprotein E (15-fold), integrin 2 (13-fold), and nonrecep-
tor tyrosine kinase 1 (12-fold). Sixty-six of the 104 genes
(63%) exhibited the alterations described in at least 3 of the
4 individual AAA specimens, including 50 of the 66 genes
(76%) exhibiting increased expression and 17 of the 39
genes (44%) exhibiting decreased expression (Table 2).
Parallel analyses between aneurysmal and normal aortic
tissues from each location are summarized by the Venn
diagram shown in Figure 3, illustrating that the patterns of
altered gene expression were quite dissimilar between
TAAs and AAAs. It is notable that quantitative increases in
expression for 97 genes were found to be unique to TAAs,
whereas increases in expression for 61 genes were found to





reference Gene or protein name NAA AAA A/N ratio P value
Conservation
(%)
E05b M87503 Interferon-stimulated transcription factor 3  5644 1379 13,606 966 2.41 .003 100
E03c U08853 Transcription factor LCR-F1 884 310 2080 244 2.35 .023 25
B02g M16038 v-yes-1 oncogene 1707 587 3953 534 2.32 .030 25
E08h M59040 CD44 antigen 3073 991 7094 521 2.31 .011 25
E02c U08191 RB 1264 117 2857 378 2.26 .007 100
F10e M21121 RANTES 7363 1838 15,804 2850 2.15 .047 50
E01k M59818 CSF-3 receptor 2319 167 4320 547 1.86 .013 100
B12d M57230 IL-6 signal transducer gp130 3567 536 1377 579 0.39 .032 75
D01n L04282 Zinc-finger protein 148 4260 225 1677 679 0.39 .011 50
D11n D26120 Zinc-finger protein 162 2567 525 977 382 0.38 .050 25
D07l M73077 Glucocorticoid receptor DNA binding factor 1 2510 434 896 394 0.36 .033 50
D09j U65928 COP9 subunit 5 4236 1085 1288 484 0.30 .048 25
B08m X06820 ras homolog gene family, member B 15,578 3944 4710 1925 0.30 .048 0
B08n U02081 Guanine nucleotide regulatory protein 4416 1051 1235 614 0.28 .040 25
D03i U18840 Myelin oligodendrocyte glycoprotein 2782 645 769 493 0.28 .048 50
D07j L01042 TATA element modulatory factor 1 2915 749 758 439 0.26 .047 50
A09i M84489 Mitogen-activated protein kinase 1 1686 133 437 336 0.26 .014 75
D12m L14754 Immunoglobulin  binding protein 2 1859 469 428 247 0.23 .036 50
B09d L37882 Frizzled homolog 2 (Drosophila) 905 126 198 159 0.22 .013 75
B14h U25265 Mitogen-activated protein kinase 5 1860 370 392 220 0.21 .014 50
F12l Z81326 Protease inhibitor 12 (neuroserpin) 1511 293 305 305 0.20 .029 75
A08g M28882 Melanoma adhesion molecule 8631 2691 1687 782 0.20 .048 25
D10l U58198 IL enhancer binding factor-1 1738 475 333 155 0.19 .031 25
D13j J03161 Serum response factor 2648 312 496 279 0.19 .002 100
D13m M88163 SWI/SNF homolog 2547 422 459 302 0.18 .007 75
D05l M21535 v-ets (avian erythroblastosis virus oncogene) 3703 863 666 431 0.18 .020 50
D07k AF069736 PCAF-associated factor 65 2215 530 332 231 0.15 .017 50
D10e X52836 Tryptophan hydroxylase 11,706 1092 1424 517 0.12 .001 100
B10e L36645 EphA4 866 291 97 97 0.11 .046 75
D01b M60974 Growth arrest and DNA damage inducible 45 9267 2748 1027 799 0.11 .028 25
F05j L15344 IL-14 514 145 49 49 0.10 .023 75
B10k M34181 Cyclic adenosine monophosphate–dependent
protein kinase 
1806 367 154 104 0.09 .005 75
D04n Z30094 General transcription factor IIH polypeptide 2 2069 712 159 151 0.08 .039 50
F11l D38595 Plasma kallikrein-sensitive glycoprotein 2216 596 168 144 0.08 .016 50
D10m M95809 General transcription factor IIH polypeptide 1 2523 350 180 97 0.07 .001 100
D14k L19871 Activating transcription factor 3 3866 1008 252 252 0.07 .013 75
B12g U48959 Myosin light chain kinase 16,148 4217 770 287 0.05 .011 25
B11g D84476 Mitogen-activated protein kinase 5 3229 1203 137 81 0.04 .043 50
B11l L36151 Pl-4-kinase  360 57 14 14 0.04 .001 100
F13a X14672 N-acetyltransferase-2 827 320 25 25 0.03 .047 75
B13g X69490 Titin 2412 686 70 57 0.03 .014 50
D11j U35143 Retinoblastoma-binding protein 7 2351 516 60 60 0.03 .005 100
B12e L11695 Transforming growth factor  receptor I 1715 599 35 35 0.02 .031 75
D13k U00115 B-cell CLL/lymphoma-6 2004 517 35 34 0.02 .009 50
D05g U26662 Neuronal pentraxin II 2413 880 27 23 0.01 .035 50
F01m D45027 R3H domain 498 201 0 0 0 .048 100
A/N, Abnormal/normal ratio.
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genes were unique to TAAs and decreases in 35 gene
products were unique to AAAs. Although 8 additional tran-
scripts were significantly altered in both TAAs and AAAs,
these alterations were directionally concordant for only 4
genes: MMP-9/gelatinase B, v-yes-1, mitogen-activated
protein kinase-9, and intracellular adhesion molecule
1/CD54 (all increased in both TAAs and AAAs). In con-
trast, the remaining genes were altered in a directionally
discordant manner, with all 4 being significantly increased
in TAAs and significantly decreased in AAAs (N-acetyl-
transferase-2, IL-6 signal transducer gp130, mitogen-acti-
vated protein kinase kinase-5, and IL enhancer binding
factor-1).
RT-qPCR
To validate the results of cDNA microarray analysis, the
patterns of messenger RNA expression for a series of se-
lected genes were independently examined with real-time
RT-qPCR. As shown in Table 3, this revealed significant
increases in expression of MMP-9/gelatinase B and v-yes-1
oncogene in both TAAs and AAAs; increased expression of
TNF-, IL-1, vascular cell adhesion molecule 1, and ca-
thepsin D in TAAs but not in AAAs; increased expression
of apolipoprotein E and IL-8 in AAAs but not in TAAs; and
increased expression of IL-6 signal transducer gp130 in
TAAs with decreased expression in AAAs. In each case, the
significance and magnitude of the alterations in expression
as detected by RT-qPCR corresponded with the results of
the microarray analysis. Thus there was a high degree of
consistency between the quantitative results obtained with
the two independent techniques.
Discussion
To better understand cellular and molecular changes that
accompany aneurysm development, cDNA microarrays
have been used to profile differences in gene expression
between normal human aorta and AAAs.33,34 To the best of
our knowledge, this investigation represents the first appli-
cation of high-throughput transcriptional profiling to degen-
erative aneurysms of the ascending thoracic aorta, thereby
providing some initial insights into molecular similarities
and differences that may exist between TAAs and AAAs.
The most important observations arising from this study
are as follows: (1) TAAs are characterized by significant
alterations in expression for at least 112 genes relative to
NTA; (2) the altered pattern of gene expression observed in
TAAs is distinguishable from that observed in AAAs with
respect to at least 208 genes, of which 101 are increased and
7 decreased in TAAs but not in AAAs and 61 are increased
and 39 decreased in AAAs but not TAAs; (3) at least 8
genes exhibit altered expression in both TAAs and AAAs,
including 4 with directionally concordant and 4 with direc-
tionally discordant changes; and (4) the greatest increases in
gene expression in TAAs were observed for the  and 
isoforms of PKC, uracil-DNA glycosylase (a DNA repair
enzyme), lymphotoxin-, TNF-, and CD27 (TNF receptor
superfamily member-7), whereas the greatest changes in
AAAs were for MMP-9/gelatinase B, CD86/B7-2 antigen,
bystin-like, apolipoprotein E, integrins 2 and 8, nonre-
ceptor tyrosine kinase 1, Janus kinase 3, IL-8, and PKC-.
These findings support the hypothesis that TAAs and AAAs
are fundamentally different pathophysiologic entities at a
molecular level, probably reflecting distinct mechanisms of
disease.
In a study of this nature, it is tempting to speculate that
individual genes exhibiting altered levels of expression in
aneurysmal tissues might be related to the pathophysiologic
events underlying aneurysm formation. However, it is im-
portant to emphasize first that in this study we examined
only established “end-stage” aneurysmal tissues from le-
sions advanced enough to require elective repair, and sec-
ond that these aneurysmal tissues were evaluated against
normal aortic tissues from comparatively young, healthy,
cadaveric organ transplant donors as control preparations.
The relative levels of gene expression found in these tissues
thus may reflect alterations related to differences in age,
microscopic atherosclerotic vascular disease, hemodynamic
stresses, and other systemic factors, as well as the presence
of aneurysmal degeneration. Furthermore, the alterations
described in these established aneurysms do not necessarily
provide insight into transcriptional alterations that might
occur at earlier stages of disease, only those present in
lesions that have enlarged enough to require repair. Al-
though altered gene expression in these tissues may actually
be more relevant to the potential clinical complications of
Figure 3. Number and distribution of genes exhibiting altered
levels of expression in aortic aneurysms. Venn diagram showing
number and distribution of 1185 genes for which significantly
altered (P < .05) or unaltered (P > .05) levels of expression were
detected in TAAs versus NTA (red) and in AAAs versus NAA
(blue) by parametric comparisons test. Numbers of genes exhib-
iting altered or unchanged levels of expression in both conditions
are illustrated by areas of overlap (purple).
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aneurysmal disease (expansion and rupture) than those that
might exist during early stages of aneurysm formation, it is
also clear that the transcriptional alterations identified in this
study will need to be confirmed at the protein level, pro-
ceeding thereafter to functional assessment of their rele-
vance in in vivo model systems. Nonetheless, with these
limitations in mind, the expression profiles derived from
this study provide a valuable start toward evaluating gene
expression patterns that characterize established aneurysmal
disease in the thoracic and abdominal aorta and, perhaps of
equal importance, determining how such patterns differ
between TAAs and AAAs.
Not surprisingly, many of the genes altered in TAAs and
AAAs are involved in intracellular signal transduction and
transcriptional activation pathways. The differences be-
tween TAAs and AAAs may therefore reflect either the
presence or absence of different cell types or the dominance
of different cellular activation and signaling pathways in
each disease. For example, two particular isoforms of PKC
were expressed at relatively high levels in TAAs versus
TABLE 3. Changes in aortic wall gene expression measured by RT-qPCR versus cDNA microarrays (n  9 genes)
Gene or protein name Thoracic P value Abdominal P value
MMP-9/gelatinase B
Aneurysmal expression (mean  SD, arbitrary units) 2.71 0.34 102 1.16 0.20 101
Normal expression (mean  SD, arbitrary units) 0.86 0.34 102 0.10 0.07 101
RT-qPCR aneurysmal/normal ratio 3.13 .001 11.8 .001
Microarray aneurysmal/normal ratio 8.64 .020 86.5 .019
IL-6 signal transducer gp130
Aneurysmal expression (mean  SD, arbitrary units) 5.74 0.85 101 6.02 0.93 101
Normal expression (mean  SD, arbitrary units) 3.54 0.56 101 1.13 0.21 102
RT-qPCR aneurysmal/normal ratio 1.62 .041 0.53 .038
Microarray aneurysmal/normal ratio 6.14 .045 0.39 .032
v-yes-1 oncogene
Aneurysmal expression (mean  SD, arbitrary units) 7.11 0.93 101 8.68 1.12 102
Normal expression (mean  SD, arbitrary units) 4.21 0.69 101 2.73 0.74 102
RT-qPCR aneurysmal/normal ratio 1.69 .019 3.17 .001
Microarray aneurysmal/normal ratio 4.75 .035 2.32 .030
Apopliporotein E
Aneurysmal expression (mean  SD, arbitrary units) 5.71 1.29 100 8.77 1.98 101
Normal expression (mean  SD, arbitrary units) 2.33 1.39 100 7.05 1.51 102
RT-qPCR aneurysmal/normal ratio 2.45 .05 12.44 .001
Microarray aneurysmal/normal ratio 2.69 .05 14.56 .018
IL-8
Aneurysmal expression (mean  SD, arbitrary units) 3.33 0.30 100 1.16 0.23 101
Normal expression (mean  SD, arbitrary units) 5.80 0.15 100 5.17 1.55 102
RT-qPCR aneurysmal/normal ratio 0.57 .05 2.24 .001
Microarray aneurysmal/normal ratio 1.01 .05 7.21 .048
IL-1
Aneurysmal expression (mean  SD, arbitrary units) 2.12 0.36 102 5.92 0.90 103
Normal expression (mean  SD, arbitrary units) 5.86 0.73 103 1.540.50 102
RT-qPCR aneurysmal/normal ratio 3.61 .001 0.38 .05
Microarray aneurysmal/normal ratio 5.41 .040 1.01 .05
TNF-
Aneurysmal expression (mean  SD, arbitrary units) 3.51 1.36 103 1.47 0.31 104
Normal expression (mean  SD, arbitrary units) 2.31 1.50 104 5.86 2.30 105
RT-qPCR aneurysmal/normal ratio 15.24 .024 2.50 .05
Microarray aneurysmal/normal ratio 26.63 .047 3.16 .05
Vascular cellular adhesion molecule 1
Aneurysmal expression (mean  SD, arbitrary units) 1.29 0.10 100 2.65 0.88 101
Normal expression (mean  SD, arbitrary units) 5.57 0.76 101 6.27 1.32 101
RT-qPCR aneurysmal/normal ratio 2.31 .001 0.42 .05
Microarray aneurysmal/normal ratio 7.81 .001 1.94 .05
Cathepsin D
Aneurysmal expression (mean  SD, arbitrary units) 4.51 1.28 101 1.52 0.94 101
Normal expression (mean  SD, arbitrary units) 1.60 0.56 101 3.53 2.94 102
RT-qPCR aneurysmal/normal ratio 2.82 .045 4.29 .05
Microarray aneurysmal/normal ratio 4.96 .002 1.34 .05
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NTA, PKC- and PKC- (100-fold and 14-fold, respec-
tively), whereas AAAs were associated with a 7-fold in-
crease in expression of PKC- but no significant alterations
in other PKC isoforms. Although regulation of PKC activity
occurs largely through phosphorylation events by upstream
mediators of cell activation, the dominant presence of cer-
tain isoforms may influence downstream events by deter-
mining how cells respond to PKC activation.37,38
With respect to other functionally-related groups of
genes, Table 1 reveals that TAAs were associated with
pronounced increases in the expression of genes involved in
regulating cell survival, proliferation, and programmed cell
death, including the DNA repair enzyme uracil-DNA gly-
cosylase (44-fold),39 lymphotoxins  (8-fold) and  (41-
fold),40 TNF- (27-fold), CD27 (a TNF receptor superfam-
ily member, 18-fold),41 platelet-derived growth factor
receptor  (11-fold), early growth response 1 (10-fold),42,
cyclins D2 (5-fold) and D3 (4-fold), jun D (7-fold), IL-1
(5-fold), and the IL-1 converting enzyme homolog ICE-
LAP3 (6-fold).43 If verified at the protein level, the in-
creased local production of soluble cytotoxic mediators,
such as TNF- and IL-1, may be particularly relevant to
the medial SMC dysfunction and depletion observed in
TAAs. Indeed, several reports have suggested that pro-
grammed cell death may play a role in the medial degen-
eration observed in TAAs,24 and it is recognized that both
TNF- and IL-1 are potent inducers of apoptosis and nitric
oxide production in cultured vascular SMCs, particularly
when acting in combination.44,45
Table 2 demonstrates that AAAs were associated with
increased expression of a number of genes related to ath-
erosclerosis and chronic inflammation that were not in-
creased in TAAs, such as those encoding the T-cell costimu-
latory molecule CD86/B7-2 antigen (43-fold),46
apoplipoprotein E (15-fold), IL-8 (7-fold), GATA-3 (7-
fold),47 nuclear factor of activated T cells (6-fold),48,49
myeloid cell nuclear differentiating antigen (5-fold), mac-
rophage stimulating 1 (4-fold), nuclear factor B p105
(4-fold), inducible nitric oxide synthase (nitric oxide syn-
thase II, 3-fold), urinary-type plasminogen activator recep-
tor (4-fold), and thrombin receptor (4-fold). Genes encoding
a number of cell adhesion molecules were also selectively
increased in AAAs, such as integrins 2 (13-fold), 8 (8-
fold), 4 (6-fold), and L (4-fold), as well as selectin E
(6-fold). Furthermore, it is notable that AAAs were associ-
ated with significantly decreased expression of growth ar-
rest and DNA damage inducible 45 (9-fold decrease),50
smooth muscle and nonmuscle myosin light chain kinase
(20-fold decrease), and transforming growth factor  recep-
tor type I (50-fold decrease), which may all reflect the
pronounced SMC depletion in AAAs.
Perhaps the most important alteration common to both
TAAs and AAAs was the marked increase in expression of
MMP-9/gelatinase B (9-fold in TAAs vs NTA and 86-fold
in AAAs vs NAA), an observation consistent with previous
studies demonstrating that production of MMP-9 is in-
creased in TAAs and dissections and in AAAs.51-53 MMP-9
is thought to contribute to elastin degradation in aneurysmal
disease, because it exhibits enzymatic activity against elas-
tic fibers and other extracellular matrix proteins and because
it is produced by medial SMC and aneurysm-infiltrating
macrophages.52,53 It has also been shown that MMP-9 is
overexpressed in various experimental animal models of
AAAs, that MMP inhibitors suppress development of ex-
perimental AAAs in rats and mice, and that mice lacking
MMP-9 are resistant to aneurysm development.35,54-57 In
the context of these observations, it appears likely that
increased expression of MMP-9 plays a central role in the
destructive remodeling of the elastic media associated with
aortic aneurysms, regardless of their location or initiating
etiology.
Although the clinical significance of this work is yet
unknown, the altered patterns of gene expression identified
here will provide a valuable foundation for further investi-
gations into the pathobiology of aortic aneurysmal disease.
This study also demonstrates that significant heterogeneity
exists between TAAs and AAAs at the molecular level and
illustrates the use of high-throughput cDNA microarrays to
generate novel information. Further applications of gene
expression profiling can be expected to substantially en-
hance our understanding of the diverse processes involved
in aneurysmal degeneration.
We thank Dr John A. Curci and Sarah J. VanVickle-Chavez for
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Discussion
Dr Frank W. Sellke (Boston, Mass). Can you comment on
how you performed the biopsies to make sure that there was
consistency between the TAA and AAA specimens? Because there
is so much, how do I put it, grungy material in aneurysms of both
types, especially AAAs, how did you take this into consideration?
Also, can you comment on the statistical analysis specific for
cDNA array technology?
Dr Absi. Thank you, Dr Sellke. With respect to the biopsies, I
obtained TAA specimens from the attending surgeons who were
performing the procedure, basically as a ring of tissue removed
when they had completed aneurysm repair. This tissue was snap-
frozen immediately in liquid nitrogen, and at a later time I ex-
tracted the messenger RNA. AAA repair was basically performed
by endoaneurysmorrhaphy, so in these cases I obtained a slice of
tissue along the whole length of aneurysm itself.
With respect to the statistical analysis, it is true that we did not
have a high number of blots. In going over the statistical analysis,
especially that provided with the software, our approach was in
agreement with literature reports indicating that with 5 blots one
can achieve reproducible results. Just because you are dealing with
1185 genes, the parametric analysis must be done with some
adjustments in a special kind of analysis of variance, such as the
Kruskal-Wallis test, which can be of help when you have a
relatively small number of samples.
Dr Michael J. Reardon (Houston, Tex). Congratulations on a
nice study and a nice presentation. I did have one question about
your normal samples. Were they from donors, or were they from
the recipients in transplants? Because if they came from donors,
they clearly came from much younger people, and there may be
altered gene expression with age. We have started taking some
plugs from the ascending aorta from coronaries to use those as
normal specimens. Would you comment on your normal speci-
mens?
Dr Absi. Thank you, Dr Reardon. I am glad that you brought
that up. That is an important issue, and we did not mean to
minimize it during the presentation. The pathophysiology of an-
eurysmal disease is thought to include numerous factors, age and
atherosclerosis among them. We chose to use donors for our
normal controls, who were young, because we did not want to bias
against any of these factors, namely age, in that situation. Age may
make a difference and at least some of the results we obtained may
be due to age. For this reason we are also planning in the future to
compare results in aneurysms with age-matched samples obtained
from patients undergoing coronary artery bypass grafting. How-
ever, if we had selected or stratified for age in this initial study we
would have tended to bias against it, and we did not want to do that
here.
Dr Anthony L. Estrera (Houston, Tex). This was a nice study.
My question is in relation to gender predominance. In our expe-
rience in Houston, our patients with thoracoabdominal and ascend-
ing arch repairs are primarily male, with a ratio of about 3:2;
whereas in our infrarenal replacements there is a greater male
predominance, about a 10:1 ratio. Do you have a comment? I
appreciate the small numbers in your study, but that would be
something to look at in the future.
Dr Absi. We simply chose our patients randomly over a certain
period of time during the conduct of the study, without selection
for gender, and agree that this will be an important issue to
examine in the future.
Dr Larry R. Kaiser (Philadelphia, Pa). You mentioned that
apolipoprotein E was 14-fold upregulated in, I think, the AAAs.
Are you concerned that the high concentration of apolipoprotein E
was due to contamination, perhaps by infiltrating foam cells in the
arterial wall, and did you use laser capture microdissection to
remove some of these foam cells and infiltrating leukocytes that
might have interfered?
Dr Absi. No, we did not use that technique, as this study was
not designed to identify the cell types or locations where the
changes in gene expression occurred, but only to provide a broad
survey of changes in gene expression within the tissue samples as
a whole. There are clearly a variety of different cell types present
within aneurysm tissues, including macrophages and vascular
smooth muscle cells, but the cells in which the changes in gene
expression were occurring were not examined in this initial inves-
tigation. This is another promising approach for the future.
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